BioLineRx (BLRX) Other Non-Current Assets (2010 - 2019)
BioLineRx (BLRX) posted quarterly Other Non-Current Assets of $59000.0 for Q3 2019, down 10.61% year-over-year from $66000.0 in Q3 2018, and down 1.67% quarter-over-quarter from $60000.0 in Q2 2019.
Powered by 
Analysis
BioLineRx (BLRX) Other Non-Current Assets (2010 - 2019) Analysis & Trends
BioLineRx's Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $59000.0 for Q3 2019.
- In Q3 2019, Other Non-Current Assets fell 10.61% year-over-year to $59000.0; the TTM figure through Sep 2019 stood at $59000.0 (down 10.61% YoY), while the FY2018 annual figure was $56000.0, down 94.4% from the prior year.
- Other Non-Current Assets for Q3 2019 stood at $59000.0, down from $60000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.0 million in Q4 2016, with the low at $50000.0 in Q1 2015.
- The 5-year median for Other Non-Current Assets is $57000.0 (2015), against an average of $255368.4.
- The sharpest annual moves came in 2017 and 2019: Other Non-Current Assets surged 1751.85% in 2017, then plunged 94.5% in 2019.
- BioLineRx's Other Non-Current Assets stood at $58000.0 in 2015, then jumped by 1624.14% to $1.0 million in 2016, then changed by 0.0% to $1.0 million in 2017, then sank by 94.4% to $56000.0 in 2018, then gained by 5.36% to $59000.0 in 2019.
- Business Quant data shows BLRX's Other Non-Current Assets at $59000.0 in Q3 2019, $60000.0 in Q2 2019, and $55000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 59,000.00 |
| Jun 30, 2019 | 60,000.00 |
| Mar 31, 2019 | 55,000.00 |
| Dec 31, 2018 | 56,000.00 |
| Sep 30, 2018 | 66,000.00 |
| Jun 30, 2018 | 63,000.00 |
| Mar 31, 2018 | 60,000.00 |
| Dec 31, 2017 | 61,000.00 |
| Sep 30, 2017 | 60,000.00 |
| Jun 30, 2017 | 53,000.00 |
| Mar 31, 2017 | 55,000.00 |
| Dec 31, 2016 | 52,000.00 |
| Sep 30, 2016 | 54,000.00 |
| Jun 30, 2016 | 54,000.00 |
| Mar 31, 2016 | 56,000.00 |
| Dec 31, 2015 | 58,000.00 |
| Sep 30, 2015 | 56,000.00 |
| Jun 30, 2015 | 57,000.00 |
| Mar 31, 2015 | 50,000.00 |
| Dec 31, 2014 | 49,000.00 |